 |
|
Funding round for OGeS
Ambitious drug developer Oxford Genome Sciences (OGeS) has secured private equity funding of an undisclosed sum from a syndicate of investors. The funding round was led by Catapult Growth Fund and included South East Growth Fund and Oxford Capital Partners.
With the funding, OeGS aims to develop personalised drug therapies for cancer and Alzheimer’s disease. The deal is the first investment for Catapult, a newly-launched £30 million fund. The other two funders have backed OeGS before.
Chief executive Christian Rohlff says that the 'additional funds provide us with financing visibility for the next three years'.
Oxford-based OGeS was founded in 2004. During the past year, the company has entered into partnerships with businesses in the therapeutic and diagnostic industries, such as US company Bayer HealthCare Diagnostics.
Related Articles |
Interesting links
Other Sector Watch
- Talking rubbish Jul 28 2008
- Crisis?– what crisis? Jul 01 2008
- Let the
drilling begin
May 13 2008 - Bargains on the high street
Mar 13 2008 - Sowing the seed Mar 03 2008
M&A News
- Buy-outs with bite Sep 30 2008
- Bob Martin tames Seven Seas Sep 30 2008
- Listed-company M&A takes a beating Sep 29 2008
- AIM welcomes San Leon Energy Sep 29 2008
- AMP acquires Fulgent Media Group Sep 26 2008
Special Offers
- 2008 AIM Guide: Jul 17 2007
- Growth Company Investor Magazine: Jul 17 2007
- Cash Shells 2007 - Research report Jul 17 2007
- Venture Capital Trusts Jul 04 2007
M&A Deals
- Redhall engineers Chieftain move Sep 30 2008
- Renold buys Indian chain business Sep 30 2008
- Sunrise in Swiss telecoms deal Sep 29 2008
- Spice is right for Mono Sep 29 2008
- Symrise sniffs out US deals Sep 26 2008
Business Diary
- Rosenblatt New Energy Awards 2009 27th February
- Business XL How to float on AIM 11th November